Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony R Mato

Showing results (21-30 of 97) with videos related to

Pageof 10
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|July 16, 2018
Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic LeukemiaErin Bange, Colleen Timlin, Charlene Kabel, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2017
Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative ReviewAnthony R Mato, Meghan C Thompson, Chadi Nabhan, et al.
Cancer Biology & Therapy|March 28, 2018
Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapiesAnthony R Mato, Jennifer C Samp, Geneviève Gauthier, et al.
Therapeutic Advances in Hematology|June 24, 2022
The potential of pirtobrutinib in multiple B-cell malignanciesJeffrey L Jensen, Anthony R Mato, Camila Pena, et al.
British Journal of Haematology|June 10, 2026
Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemiaJohanne U Hermansen, Yanping Yin, Geir E Tjønnfjord, et al.
American Journal of Hematology|September 20, 2022
Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare)Julia H Aronson, Sigrid S Skånland, Lindsey E Roeker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2025
Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic LeukemiaYanping Yin, Haifeng Xu, Liye He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2020
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte)Elise A Chong, Lindsey E Roeker, Mazyar Shadman, et al.
Leukemia & Lymphoma|October 3, 2018
Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United StatesRavi K Goyal, Saurabh P Nagar, Shaum M Kabadi, et al.
Hemasphere|December 26, 2022
COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic LeukemiaMazyar Shadman, Catherine Liu, Katherine Eakle, et al.
Pageof 10

Showing results (21-30 of 97) with videos related to

Sort By:
Pageof 10
Clinical Lymphoma, Myeloma & Leukemia|July 16, 2018
Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic LeukemiaErin Bange, Colleen Timlin, Charlene Kabel, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2017
Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative ReviewAnthony R Mato, Meghan C Thompson, Chadi Nabhan, et al.
Cancer Biology & Therapy|March 28, 2018
Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapiesAnthony R Mato, Jennifer C Samp, Geneviève Gauthier, et al.
Therapeutic Advances in Hematology|June 24, 2022
The potential of pirtobrutinib in multiple B-cell malignanciesJeffrey L Jensen, Anthony R Mato, Camila Pena, et al.
British Journal of Haematology|June 10, 2026
Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemiaJohanne U Hermansen, Yanping Yin, Geir E Tjønnfjord, et al.
American Journal of Hematology|September 20, 2022
Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare)Julia H Aronson, Sigrid S Skånland, Lindsey E Roeker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2025
Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic LeukemiaYanping Yin, Haifeng Xu, Liye He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2020
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte)Elise A Chong, Lindsey E Roeker, Mazyar Shadman, et al.
Leukemia & Lymphoma|October 3, 2018
Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United StatesRavi K Goyal, Saurabh P Nagar, Shaum M Kabadi, et al.
Hemasphere|December 26, 2022
COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic LeukemiaMazyar Shadman, Catherine Liu, Katherine Eakle, et al.
Pageof 10